论文部分内容阅读
目的探讨孟鲁司特钠联合布地奈德治疗支气管哮喘患儿的临床效果。方法选取2013年1月至2014年2月于沈阳市儿童医院就诊并接受治疗的106例支气管哮喘患儿作为研究对象,按照患儿入院时间先后分为观察组与对照组,各53例。两组患儿均给予常规对症治疗,同时对照组患儿雾化吸入布地奈德气雾剂,观察组患儿在对照组基础上口服孟鲁司特钠片,比较两组患儿临床疗效、治疗前后肺功能、症状消失时间及不良反应发生情况。结果观察组患儿治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组患儿的第1秒钟用力呼气容积(FEV1)、呼气高峰流量(PEFR)、用力肺活量(FVC)均明显高于对照组,差异均有统计学意义(均P<0.05);观察组患儿肺部哮鸣音、肺部湿性啰音、哮喘、咳嗽消失时间均明显短于对照组,差异均有统计学意义(均P<0.05)。结论孟鲁司特钠联合布地奈德治疗支气管哮喘患儿效果显著,可有效改善肺功能,促进患儿早日康复,且不良反应发生率较低。
Objective To investigate the clinical effect of montelukast combined with budesonide in the treatment of children with bronchial asthma. Methods From January 2013 to February 2014, 106 children with bronchial asthma treated and treated in Children’s Hospital of Shenyang were enrolled and divided into observation group and control group according to their admission time, each with 53 cases in each group. The two groups of children were given conventional symptomatic treatment, while the control group of children inhaled budesonide aerosol, the observation group of children on the basis of the control group oral montelukast sodium tablets, the clinical efficacy of two groups were compared, Before and after treatment of lung function, symptoms disappear time and adverse reactions. Results The total effective rate of observation group was significantly higher than that of control group (P <0.05). After treatment, forced expiratory volume in 1 second (FEV1) and peak expiration PEFR and FVC in the observation group were significantly higher than those in the control group (all P <0.05). The lung wheeze, lung wet rales, asthma and cough disappeared in the observation group Time were significantly shorter than the control group, the differences were statistically significant (P <0.05). Conclusion Montelukast combined with budesonide in children with bronchial asthma significantly, can effectively improve lung function and promote the early recovery of children, and the incidence of adverse reactions is low.